NASDAQ:ENVB - Enveric Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.50
  • Forecasted Upside: 238.54 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.92
▼ -0.1 (-4.95%)

This chart shows the closing price for ENVB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enveric Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENVB

Analyst Price Target is $6.50
▲ +238.54% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Enveric Biosciences in the last 3 months. The average price target is $6.50, with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 238.54% upside from the last price of $1.92.

This chart shows the closing price for ENVB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Enveric Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/8/2021AegisInitiated CoverageBuy$7.00High
6/28/2021Maxim GroupInitiated CoverageBuy$6.00High
(Data available from 7/23/2016 forward)
Enveric Biosciences logo
Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.
Read More

Today's Range

Now: $1.92
Low: $1.91
High: $2.06

50 Day Range

MA: $2.25
Low: $1.92
High: $2.72

52 Week Range

Now: $1.92
Low: $1.81
High: $15.04

Volume

387,471 shs

Average Volume

3,955,396 shs

Market Capitalization

$41.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Enveric Biosciences?

The following Wall Street sell-side analysts have issued stock ratings on Enveric Biosciences in the last year: Aegis, and Maxim Group.
View the latest analyst ratings for ENVB.

What is the current price target for Enveric Biosciences?

2 Wall Street analysts have set twelve-month price targets for Enveric Biosciences in the last year. Their average twelve-month price target is $6.50, suggesting a possible upside of 238.5%. Aegis has the highest price target set, predicting ENVB will reach $7.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for Enveric Biosciences in the next year.
View the latest price targets for ENVB.

What is the current consensus analyst rating for Enveric Biosciences?

Enveric Biosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENVB will outperform the market and that investors should add to their positions of Enveric Biosciences.
View the latest ratings for ENVB.

What other companies compete with Enveric Biosciences?

How do I contact Enveric Biosciences' investor relations team?

Enveric Biosciences' physical mailing address is 4080 MCGINNIS FERRY ROAD SUITE 1306, ALPHARETTA GA, 30005. The company's listed phone number is (239) 302-1707 and its investor relations email address is [email protected] The official website for Enveric Biosciences is jaypharma.co.